SILVER SPRING, Md., March 27, 2025 /PRNewswire/ -- Urban One, Inc. UONEK today reported its results for the three months ended December 31, 2024. For the three months ended December 31, 2024, net revenue was approximately $117.1 million, a decrease of 2.7% from the same period in 2023.

Rocket Lab USA ( NASDAQ: RKLB ) has been on an incredible run, with its stock skyrocketing some 400% in the past year. The rocket company recently celebrated a record year for launches, solidifying its position as the second-most-utilized launch service in the U.S., right behind the industry ...

NASHVILLE, Tenn., March 27, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. BKD ( "Brookdale" or the "Company" ) today announced that it has elected to exercise its right to settle all of its prepaid stock purchase contracts, pursuant to the early settlement right in the purchase contract ...

HONG KONG, March 27, 2025 ( GLOBE NEWSWIRE ) -- UCLOUDLINK GROUP INC. ( "UCLOUDLINK" or the "Company" ) UCL, the world's first and leading mobile data traffic sharing marketplace, today announced its participation as a sponsor of the LD Micro Invitational XV taking place April 9-10, 2025, at the ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted. Pharmaceutical titan Pfizer ( NYSE: PFE ) is a case in point.The drugmaker's shares ...

Specific patterns often repeat in the stock market. For example, small, unprofitable companies that surge based on hype tend to give back their gains quickly. SoundHound AI ( NASDAQ: SOUN ) is a great example. Shares of the audio-focused AI start-up boomed after tech giant Nvidia revealed that it ...

- Presented preclinical non-human primate ( NHP ) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 ( ECCO ) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A.

TULIKIVI CORPORATION STOCK EXCHANGE RELEASE 27 MARCH 2025 AT 1:00 P.M. ...

- Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader - - Company to highlight first-in-human data from healthy volunteers in both the ...

First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in ...